Home > NRC Library > ADAMS Public Documents

Amend 7 to License 40-16571-01 for McKennan Hosp,authorizing use of any byproduct matl for medical uses described in 10CFR35.100,35.200,35.300,35.400 & 35.500 & in vitro studies.

Accession Number: ML20235L112

Date Released: Wednesday, October 23, 2024

Package Contents

The following links on this page are to Adobe Portable Document Format (PDF) files. To obtain a free viewer for displaying this format, see our Plugins, Viewers, and Other Tools.

• ML20235L153 - Submits addl info requested in 870312 ltr,including correct ref guide of Rev 1 to Reg Guide 10.8 & ltr verifying that all pertinent matl in application,including statements & & representations reviewed. (2 page(s), 3/25/1987)
• ML20235L191 - Certifies that application packet for renewal of License 40-16571-01 reviewed & concurs w/all statements & representations made.Related info encl. (12 page(s), 3/25/1987)
• ML20235L242 - Requests listed addl info re 860513 application for renewal of License 40-16571-01,including confirmation of ref of Reg Guide 10.8,Rev 1 & date requested at top of Page 2 of Form NRC-313M & package opening procedures. (3 page(s), 3/12/1987)
• ML20235L366 - Ack receipt of application for renewal of License 40-16571-01. (1 page(s), 9/4/1986)
• ML20235L385 - Informs that unless addl fee for 860513 application for renewal of License 40-16571-01 received within 30 days, application will be considered abandoned. (1 page(s), 8/22/1986)
• ML20235L403 - Requests payment of addl fee re 860513 application for renewal of License 40-16571-01. (2 page(s), 6/5/1986)
• ML20235L439 - Application for renewal of License 40-16571-01,authorizing use of I-131 as iodine for treatment of hyperthyroidism, adding MA Tajiran & deleting TR Anderson.Fee paid. (1 page(s), 5/13/1986)